Acute myeloid leukemia (AML), the most common form of leukemia in adults, is associated with poor five-year overall survival rates. After years of chemotherapy-dominated treatment, the FDA approved four drugs for AML in 2017 (Pfizer’s Mylotarg, Novartis’s Rydapt, Agios’s Idhifa, and Jazz’s Vyxeos) and an additional four drugs in 2018 (Agios’s Tibsovo, AbbVie’s Venclexta, Pfizer’s Daurismo, and Astellas’s Xospata).
In light of impressive data for multiple newly approved drugs in AML subpopulations, the treatment paradigm is changing rapidly by shifting toward increasingly targeted and personalized therapies.
- Following the FDA approval of eight drugs for AML since 2017, how do physicians incorporate these additional therapy options into their practices?
- What is the uptake of AbbVie’s Venclexta in patients ineligible for intensive induction? Which Venclexta combinations are prescribed most frequently?
- Is Astellas’s Xospata prescribed for FLT3-mutation-positive patients in the relapsed/refractory setting? How is the drug’s uptake affected by prescribing of other FLT3 inhibitors, including Novartis’s Rydapt in the previously untreated setting or Nexavar in the relapsed/refractory setting?
- What will be the uptake of IDH inhibitors in patients with IDH mutations?
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States.
Primary research: Survey of ~100 hematologist-oncologists in the United States.
Key drugs covered: Venclexta, Xospata, Idhifa, Tibsovo, Vyxeos, Daurismo, Mylotarg, Rydapt.
- Acute Myeloid Leukemia - Current Treatment - Detailed, Expanded Analysis (US)
- Current Treatment Physician Insights Acute Myeloid Leukemia US April 2020
Author(s): Sudha Malhotra, Ph.D; Dana Gheorghe
Sudha Malhotra joined Decision Resource Group in 2018. She is responsible for performing secondary market analysis including patent research, pricing, and clinical trial assessment for major pharmaceutical markets covering a wide range of oncology indications. She obtained her doctorate degree in life sciences from the National Institute of Immunology, New Delhi, India and has authored several original peer-reviewed journal articles. She holds a bachelor’s degree in microbiology and a master’s degree in biomedical sciences both from the University of Delhi, India.
Dana Gheorghe, Ph.D., is a senior business insights analyst on the Oncology team at Decision Resources Group, specializing in non-Hodgkin’s lymphoma and renal cell carcinoma, with expertise in multiple myeloma and metastatic colorectal cancer. Her previous experience includes postdoctoral positions at Imperial College London and the Marie Curie Research Institute. Dr. Gheorghe holds a Ph.D. in cellular biology and biochemistry from the University of Sheffield and a B.Sc./Honors in Molecular Biology from the University of Edinburgh.